Abstract 388P
Background
Bevacizumab (Avastin®) is a monoclonal antibody targeting the vascular endothelial growth factor (VEGF). Used alone or in combination with chemotherapy and/or immunotherapy, there is confirmed efficacy in many cancers.
Methods
In this randomized, double-blind, multicenter, phase III, treatment naive, locally advanced, metastatic, or recurrent EGFR wildtype non-squamous, non small cell lung cancer (nsNSCLC) patients were enrolled and randomized (1:1) into TAB008 or Avastin® groups. Patients received 4-6 (3 week)cycles of paclitaxel/carboplatin plus TAB008 or Avastin® at 15mg/kg intravenously, followed by 7.5mg/kg maintenance dose until disease progression, unacceptable toxicity, or death. The primary endpoint compared the objective response rate (ORR) within 6 cycles as read by an independent radiological review committee (IRRC). Secondary endpoints included disease control rate (DCR), duration of response (DoR), progression free survival (PFS), 1 year overall survival rate (OSR), overall survival (OS), safety, immunogenicity, and pharmacological bio-equivalence of Cmin under steady state conditions.
Results
A total of 549 nsNSCLC patients were enrolled (277 in the TAB008 group, 272 in the Avastin® group). In the full analysis set, ORRs were 55.957% for TAB008, and 55.720% for Avastin®, the 90% CI was 0.89-1.14, well within the predefined equivalence margin of 0.75-1.33. No significant differences were found in DCR within 6 cycles (95.7% vs 95.4%, p=0.8536), DoR (8.17 vs 7.3 months, p=0.3526), PFS (9.10 vs 7.97 months, p=0.9457), 1 year OSR (66.2 vs 68%, p=0.6793), or OS (20.4 vs 17.4 months, p=0.6594). Serious adverse events (AEs) occurred in 37.55% (104/277) and 34.32% (93/271) in the TAB008 and Avastin® groups. Anti-drug antibodies were reported in 3/277 (1.08%) and 5/271(1.85%) in the TAB008 and Avastin® groups. Steady-state trough concentrations (Cmin) were 106.13 and 96.03μg/mL in the TAB008 and Avastin® groups, with the treatment group ratio of LS geometric means is contained within the bioequivalence limits of 80.00–125.00% (90% CI: 101.74%-120.05%).
Conclusions
TAB008 is similar to bevacizumab(Avastin®) in terms of efficacy, safety, and pharmacokinetic parameters.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
TOT BIOPHARM.
Funding
TOT BIOPHARM.
Disclosure
X. Li, L. Wang: Full/Part-time employment: TOT BIOPHARM. All other authors have declared no conflicts of interest.
Resources from the same session
14P - BRCA mutation and clinical outcomes in breast cancer focusing on survivals and failure patterns: A long-term follow-up study of Koreans
Presenter: Hakyoung Kim
Session: e-Poster Display Session
15P - Designing of multimodal targeted tumor-seeking nanomedicine for triple-therapeutic effect
Presenter: Vellingiri Yasothamani
Session: e-Poster Display Session
16P - Topical henna cream in prevention of radiation-induced dermatitis in breast cancer: A randomized double-blind clinical trial
Presenter: Mansour Lesan
Session: e-Poster Display Session
17P - Comparison of dose distribution in the postoperative breast cancer patients irradiated with the technique of deep inspiratory breath hold and dynamic techniques
Presenter: Ewa Telka
Session: e-Poster Display Session
18P - A prospective randomized study comparing cosmetic outcome of sequential electron boost versus simultaneous integrated boost with IMRT to lumpectomy cavity during adjuvant radiotherapy to breast following BCS in carcinoma breast in Indian patients
Presenter: Sravya Bommera
Session: e-Poster Display Session
19P - Musculoskeletal pain and health-related quality of life among breast cancer patients
Presenter: Aslin Valiyagath
Session: e-Poster Display Session
20P - Molecular parallelisms and divergences between human and canine cancers
Presenter: Sadaf Ambreen
Session: e-Poster Display Session
21P - Neoadjuvant trastuzumab and pertuzumab in real-world data population in two medical institutions in Portugal
Presenter: Isabel Gomes Fernandes
Session: e-Poster Display Session
22P - Correlation of muscle strength and quality of life in Indonesian breast cancer patients who underwent chemotherapy
Presenter: Devina Halim
Session: e-Poster Display Session
23P - Oncotype DX RS correlation with clinicopathologic risk factors and chemotherapy: Follow up based on TAILORx study
Presenter: Faroug Ali
Session: e-Poster Display Session